Ion binding polymers and uses thereof

Details Ion binding polymers and uses thereof Ion binding polymers and uses thereof

2004-10-13

2009-02-10

Richter, Johann R. (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

C424S400000, C424S483000

Reexamination Certificate

active

07488495

ABSTRACT:
The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

REFERENCES:
patent: 2611730 (1952-09-01), Heming et al.
patent: 2909462 (1959-10-01), Warfield et al.
patent: 3499960 (1970-03-01), Macek et al.
patent: 3974272 (1976-08-01), Polli et al.
patent: 4143130 (1979-03-01), Imondi
patent: 4470975 (1984-09-01), Berger
patent: 4605701 (1986-08-01), Harada et al.
patent: 4747881 (1988-05-01), Shaw et al.
patent: 4837015 (1989-06-01), Olsen
patent: 4902501 (1990-02-01), Bandi et al.
patent: 4942205 (1990-07-01), Ohmori et al.
patent: 5051253 (1991-09-01), Lloyd-Jones
patent: 5091175 (1992-02-01), Imondi et al.
patent: 5141927 (1992-08-01), Krotkiewski
patent: 5186937 (1993-02-01), Sparks et al.
patent: 5281631 (1994-01-01), Horwitz
patent: 5374422 (1994-12-01), Pierre
patent: 5487888 (1996-01-01), Mandeville, III et al.
patent: 5607669 (1997-03-01), Mandeville
patent: 5618530 (1997-04-01), Mandeville, III et al.
patent: 5633344 (1997-05-01), Figuly
patent: 5667775 (1997-09-01), Holmes-Farley et al.
patent: 5679717 (1997-10-01), Mandeville, III et al.
patent: 5693675 (1997-12-01), Mandeville, III et al.
patent: 5702696 (1997-12-01), Mandeville, III et al.
patent: 5718920 (1998-02-01), Notenbomer
patent: 5935599 (1999-08-01), Dadey
patent: 6294163 (2001-09-01), Dhal
patent: 6881484 (2005-04-01), Kataoka et al.
patent: 2002/0054903 (2002-05-01), Tyler et al.
patent: 2002/0146386 (2002-10-01), Simon et al.
patent: 2003/0027789 (2003-02-01), Yamaoka et al.
patent: 2003/0065090 (2003-04-01), Kelly et al.
patent: 2004/0166156 (2004-08-01), Tyler et al.
patent: 2004/0251204 (2004-12-01), Paananen et al.
patent: 2005/0036983 (2005-02-01), Simon et al.
patent: 2005/0220752 (2005-10-01), Charmot et al.
patent: 2005/0220889 (2005-10-01), Charmot et al.
patent: 2005/0220890 (2005-10-01), Charmot et al.
patent: 2006/0024336 (2006-02-01), Charmot et al.
patent: 0349453 (1989-04-01), None
patent: 0730494 (1998-02-01), None
patent: 1998059851 (1998-03-01), None
patent: 1998130154 (1998-05-01), None
patent: 0 730 494 (1998-02-01), None
patent: WO 82/00257 (1982-02-01), None
patent: WO 92/10522 (1992-06-01), None
patent: WO 94/27619 (1994-12-01), None
patent: WO 95/14531 (1995-06-01), None
patent: 9749387 (1997-12-01), None
patent: WO 97/49736 (1997-12-01), None
patent: 0040224 (2000-07-01), None
patent: WO 01/51063 (2001-07-01), None
patent: WO 02/12160 (2002-02-01), None
patent: WO 02/40039 (2002-05-01), None
patent: WO 02/062356 (2002-08-01), None
patent: WO 2005/065291 (2005-07-01), None
Berlyne, G.M., et al. “Cation exchange resins in hyperkalaemic renal failure.” (1967) Israel J Med Sci 3(1): 45-52.
Chourasia, M.K., et al., “Pharmaceutical approaches to colon targeted drug delivery systems.” (2003) J. Pharm Pharm Sci 6(1): 33-66.
Corcoran, A.C., et al., “Controlled observations on the effect of low sodium dietotherapy in essential hypertension.” (1951) Circulation 3(1): 1-16.
Danowski, T.S., et al., “Changes in fecal and serum constituents during ingestion of cation and anion exchangers.” (1953) Ann N Y Acad Sci. 57(3): 273-9.
Emerson, K., Jr. , et al., “The role of the gastro-intestinal tract in the adaptation of the body to the prevention of sodium depletion by cation exchange resins.” (1953) Ann N Y Acad Sci. 57(3): 280-90.
Emmett, M., et al. “Effect of Three Laxatives and a Cation Exchange Resin on Fecal Sodium and Potassium Excretion.” (1995) Gastroenterology 108(3): 752-60.
Evans, B.M., et al. “Ion-exchange resins in the treatment of anuria.” (1953) Lancet 265(6790): 791-5.
Field, H., Jr., et al., “Electrolyte changes in ileal contents and in feces during restriction of dietary sodium with and without the administration of cation-exchange resin.” (1955) Circulation 12(4): 625-9.
Field, H., Jr., et.al., “Mechanisms regulating the retention of sodium in the feces by cation-exchange resin: release of base from the resin by bacterial fermentation in the terminal ileum.” (1958) J Lab Clin Med 51(2): 178-84.
Fourman, P. “Capacity of a cationic exchange resin (zeo-karb 225) in vivo.” (1953) British Medical Journal 1(4809): 544-6.
Greenman, L., et al. “Biochemical changes accompanying the ingestion of a carboxylic cation exchanger in the hydrogen, ammonium, sodium, potassium, or calcium form.” (1951) J Clin Invest. 30(9): 995-1008.
Gruy-Kapral, C., et al., “Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease.” (1998) J Am Soc Nephrol 9(10): 1924-30.
Harthon, J.G.L., et al., “A Case of Uremia and Hyperpotassemia Treated With Sulphonic Cation-Exchange Resin” (1952) Acta Med Scan., 144(3): 230-6.
Heming A. E., et al., “Considerations in the selection of cation exchange resins for therapeutic use.” (1953) Ann N Y Acad Sci. 57(3):239-51.
Irwin, L., et al. “The effect of a cation exchange resin on electrolyte balance and its use in edematous states.” (1949) J Clin Invest. 28(6, Pt. 2): 1403-11.
Kohlstaedt, K.G., et al., “Clinical experience with mixtures of anion and cation exchange resins.” (1953) Ann N Y Acad Sci. 57(3): 260-72.
Mason N.S., et al., “A new ion exchanger with high in vivo sodium capacity.” (1985) Kidney Int Suppl. 28(17): S178-182.
Mateer, F.M., et al., “Sodium Restriction and Cation Exchange Resin Therapy in Nephrotic Children” (1951) J Clin Invest. 30(9): 1018-26.
McChesney, E.W. “Effects of long-term feeding of sulfonic ion exchange resin on the growth and mineral metabolism of rats.” (1954) Am J Physiol. 177(3):395-400.
McChesney, E.W., et al., “Some aspects of cation exchange resins as therapeutic agents for sodium removal.” (1953) Ann N Y Acad Sci. 57(3):252-9.
Moustafine R.I., et al., “Characteristics of interpolyelectrolyte complexes of Eudragit E 100 with sodium alginate.” (2005) Int J Pharm 294(1-2): 113-20.
Root, M.A., “Comparison of the in vivo sodium-removing activity of various types of ion exchange resins in rats.” (1953) J Lab Clin Med 42(3): 430-7.
Ross, E.J., et al. “Observations on cation exchange resins in the small and large intestines.” (1954) Clin Sci 13(4): 555-66.
Tust, R. H., et al., “The Effects of Malethamer on the Excretion and Plasma Levels of Sodium, Potassium, and Chloride (34990)” (1970) Proc Soc Exp Biol Med. 135(1): 72-6.
Wrong, O., et al., “The electrolyte content faeces.” (1965) Proc R. Soc Med 58(12): 1007-9.
Coli, L. et al. 1992. Phosphate Removal by Resin Hemoperfusion Efficacy and Biocompatibility of a New Exchange Resin.Biomaterials, Artificial Cells, and Immobilization Biotechnology.20(5): 1153-1163.
Forrest, M. Laird, et al. 2003. A Degradable Polyethylenimine Derivative with Low Toxicity for Highly Efficient Gene Delivery.Bioconjugate Chem.14(5): 934-940.
Koping-Hoggard, M. et al. 2001. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo.Gene Therapy.8: 1108-1121.
Thomas, Mini, etal. 2005. Cross-linked Small Polyethylenimines: While Still Nontoxic, Deliver DNA Efficiently to Mammalian Cells in Vitro and in Vivo.Pharmaceutical Research.22(3): 373-380.
Friedman, Eli A. , Clinical Aspects of Uremia and Dialysis/ Sorbent Therapy in Uremia 671-687. (Shaul G. Massry & Alvin L. Sellers eds., 1976).
Friedman, Eli A., et al. 1976. Combined oxystarch-charcoal trial in

Affiliated with

Also associated with

Rating

Ion binding polymers and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ion binding polymers and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ion binding polymers and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4054092